Pre-earnings options volume in Adma Biologics (ADMA) is 2.5x normal with calls leading puts 10:3. Implied volatility suggests the market is anticipating a move near 12.3%, or $1.27, after results are released. Median move over the past eight quarters is 9.9%.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ADMA:
- Analyst Reaffirms Buy Rating on ADMA Biologics, Citing Expanded Asceniv FDA Label and Strong Growth Outlook Despite Bivigam Concerns
- Adma Biologics announces FDA approval for Asceniv sBLA
- ADMA Biologics Gains FDA Approval for Expanded ASCENIV Label
- ADMA Earnings this Week: How Will it Perform?
- CrowdStrike, ADMA, Achieve, AbbVie, Valero Trending With Analysts